Anabolic androgenic steroids and cardiomyopathy: an update
Anabolic androgenic steroids (AAS) include endogenously produced androgens like testosterone and their synthetic derivatives. Their influence on multiple metabolic pathways across organ systems results in an extensive side effect profile. From creating an atherogenic and prothrombotic milieu to dire...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-07-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1214374/full |
| _version_ | 1827892879264055296 |
|---|---|
| author | Kahtan Fadah Gokul Gopi Ajay Lingireddy Vanessa Blumer Tracy Dewald Robert J. Mentz |
| author_facet | Kahtan Fadah Gokul Gopi Ajay Lingireddy Vanessa Blumer Tracy Dewald Robert J. Mentz |
| author_sort | Kahtan Fadah |
| collection | DOAJ |
| description | Anabolic androgenic steroids (AAS) include endogenously produced androgens like testosterone and their synthetic derivatives. Their influence on multiple metabolic pathways across organ systems results in an extensive side effect profile. From creating an atherogenic and prothrombotic milieu to direct myocardial injury, the effects of AAS on the heart may culminate with patients requiring thorough cardiac evaluation and multi-disciplinary medical management related to cardiomyopathy and heart failure (HF). Supraphysiological doses of AAS have been shown to induce cardiomyopathy via biventricular dysfunction. Advancement in imaging including cardiac magnetic resonance imaging (MRI) and additional diagnostic testing have facilitated the identification of AAS-induced left ventricular dysfunction, but data regarding the impact on right ventricular function remains limited. Emerging studies showed conflicting data regarding the reversibility of AAS-induced cardiomyopathy. There is an unmet need for a systematic long-term outcomes study to empirically evaluate the clinical course of cardiomyopathy and to assess potential targeted therapy as appropriate. In this review, we provide an overview of the epidemiology, pathophysiology and management considerations related to AAS and cardiomyopathy. |
| first_indexed | 2024-03-12T21:46:19Z |
| format | Article |
| id | doaj.art-6fd1e0a90db946ef9f1c2230e0a0a3fc |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-03-12T21:46:19Z |
| publishDate | 2023-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-6fd1e0a90db946ef9f1c2230e0a0a3fc2023-07-26T11:17:04ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2023-07-011010.3389/fcvm.2023.12143741214374Anabolic androgenic steroids and cardiomyopathy: an updateKahtan Fadah0Gokul Gopi1Ajay Lingireddy2Vanessa Blumer3Tracy Dewald4Robert J. Mentz5Division of Cardiovascular Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United StatesDepartment of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, NY, United StatesDivision of Cardiovascular Medicine, Department of Internal Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, United StatesDepartment of Cardiovascular, Heart and Vascular Institute, Kaufman Center For Heart Failure, OH, United StatesDepartment of Cardiovascular, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, United StatesDepartment of Cardiovascular, Duke University Medical Center and Duke Clinical Research Institute, Durham, NC, United StatesAnabolic androgenic steroids (AAS) include endogenously produced androgens like testosterone and their synthetic derivatives. Their influence on multiple metabolic pathways across organ systems results in an extensive side effect profile. From creating an atherogenic and prothrombotic milieu to direct myocardial injury, the effects of AAS on the heart may culminate with patients requiring thorough cardiac evaluation and multi-disciplinary medical management related to cardiomyopathy and heart failure (HF). Supraphysiological doses of AAS have been shown to induce cardiomyopathy via biventricular dysfunction. Advancement in imaging including cardiac magnetic resonance imaging (MRI) and additional diagnostic testing have facilitated the identification of AAS-induced left ventricular dysfunction, but data regarding the impact on right ventricular function remains limited. Emerging studies showed conflicting data regarding the reversibility of AAS-induced cardiomyopathy. There is an unmet need for a systematic long-term outcomes study to empirically evaluate the clinical course of cardiomyopathy and to assess potential targeted therapy as appropriate. In this review, we provide an overview of the epidemiology, pathophysiology and management considerations related to AAS and cardiomyopathy.https://www.frontiersin.org/articles/10.3389/fcvm.2023.1214374/fullanabolic androgenic steroidscardiomyopathyheart failuremyocardial injuryventricular dysfunction |
| spellingShingle | Kahtan Fadah Gokul Gopi Ajay Lingireddy Vanessa Blumer Tracy Dewald Robert J. Mentz Anabolic androgenic steroids and cardiomyopathy: an update Frontiers in Cardiovascular Medicine anabolic androgenic steroids cardiomyopathy heart failure myocardial injury ventricular dysfunction |
| title | Anabolic androgenic steroids and cardiomyopathy: an update |
| title_full | Anabolic androgenic steroids and cardiomyopathy: an update |
| title_fullStr | Anabolic androgenic steroids and cardiomyopathy: an update |
| title_full_unstemmed | Anabolic androgenic steroids and cardiomyopathy: an update |
| title_short | Anabolic androgenic steroids and cardiomyopathy: an update |
| title_sort | anabolic androgenic steroids and cardiomyopathy an update |
| topic | anabolic androgenic steroids cardiomyopathy heart failure myocardial injury ventricular dysfunction |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2023.1214374/full |
| work_keys_str_mv | AT kahtanfadah anabolicandrogenicsteroidsandcardiomyopathyanupdate AT gokulgopi anabolicandrogenicsteroidsandcardiomyopathyanupdate AT ajaylingireddy anabolicandrogenicsteroidsandcardiomyopathyanupdate AT vanessablumer anabolicandrogenicsteroidsandcardiomyopathyanupdate AT tracydewald anabolicandrogenicsteroidsandcardiomyopathyanupdate AT robertjmentz anabolicandrogenicsteroidsandcardiomyopathyanupdate |